Clinical Trial Update: Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500 [Phase 3]

View source ↗

Summary

A Phase 3 placebo-controlled, double-blind crossover study of KW-6500 for Parkinson's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• KW-6500

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Parkinson's Disease | Phase 3 | Status: COMPLETED